Answers are grounded in this paper and cite their sources.
Demonstrates allantoin's dose-dependent effects on proliferation and oxidative resilience in embryonic palatal cells, suggesting therapeutic potential.
Background: Cleft palate is a congenital craniofacial anomaly that originates from disrupted palatogenesis. During palatal shelf morphogenesis, palatal mesenchyme must expand, remodel, and withstand environmental stress, and oxidative imbalance is considered a convergent cellular risk that can compromise developmental robustness. Allantoin is a clinic-friendly small molecule widely used in topical formulations and reported to modulate cell behavior, but its dose-dependent effects and antioxidant mechanism in embryonic palatal mesenchyme remain unclear. Here, we investigated the concentration window and Nrf2-related cytoprotective mechanism of allantoin in mouse embryonic palatal mesenchymal (MEPM) cells. Methods: MEPM cells were isolated from E14.5 mouse palatal shelves and treated with allantoin (0.5–5 mg/mL). Cytotoxicity and time-dependent growth were assessed by CCK-8 and growth index analysis. Mesenchymal motility was evaluated using a scratch assay. For cytoprotection, cells were pretreated with allantoin for 24 hours and challenged with 0.1% (w/v) H 2 O 2 for 2 hours, followed by Annexin V-FITC/7-AAD flow cytometry. Osteogenic and chondrogenic differentiation were induced for 21 days with lower-dose allantoin (0–2 mg/mL) and assessed by Alizarin Red S and Alcian Blue staining with ImageJ quantification. Nrf2 pathway activation was analyzed by RT-qPCR and Western blotting (Nrf2, HO-1, NQO1), and pharmacological inhibition was performed with ML385. Results: Allantoin was noncytotoxic across 0.5 to 5 mg/mL and enhanced early proliferative capacity, with the strongest growth-promoting effect observed at intermediate concentrations. Allantoin increased wound closure, indicating improved mesenchymal motility. Under oxidative challenge, allantoin reduced apoptosis and restored viability with maximal protection at 3 to 4 mg/mL. Mechanistically, allantoin upregulated Nrf2 and its downstream targets HO-1 and NQO1 at both mRNA and protein levels, while ML385 partially attenuated these responses. In contrast, higher concentrations during lineage induction (1–2 mg/mL) tended to suppress osteogenic mineralization and chondrogenic matrix formation. Conclusions: Allantoin supports palatogenesis-relevant MEPM cell behaviors, including early growth, mesenchymal motility, and resilience to oxidative stress, within an optimal concentration window (∼3–4 mg/mL). Allantoin’s cytoprotective effects are associated with activation of the Nrf2/HO-1/NQO1 antioxidant program. Given the dose-sensitive suppression of osteo-/chondrogenic differentiation at higher exposure, future applications should prioritize dose- and time-controlled designs and validate findings in palatal shelf organ culture and embryonic palatogenesis models.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: